Hsiri Therapeutics is a groundbreaking brand dedicated to the discovery and development of therapies for infections caused by drug-resistant bacteria. With a focus on infections caused by mycobacteria, usual bacterial pathogens resistant to current treatments, and drug-resistant fungal pathogens, Hsiri Therapeutics is at the forefront of combating these challenging medical issues. Their research concepts, which form the foundation of their products, originate from the groundbreaking work of Professor Marvin Miller at the University of Notre Dame.

This ensures that their treatments are backed by scientific expertise and innovation. In exciting news, Hsiri Therapeutics has entered into a new license agreement and research collaboration with Shionogi & Co. This partnership aims to further expand their efforts in treating mycobacterial diseases, paving the way for novel therapeutics that can make a significant impact in healthcare.

Hsiri Therapeutics' dedication to finding solutions to drug-resistant infections makes them a vital player in the field of medical research and development